Trial Profile

A Phase III multicenter, open-label, single-arm Clinical Trial of sparsentan in Japanese patients with IgA nephropathy.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jan 2025 According to a Renalys Pharma media release, Results from the urine protein/creatinine ratio (UP/C) endpoint in the study are expected in the second half of 2025 to support a submission for approval to PMDA.
30 Jan 2025 Status changed from recruiting to active, no longer recruiting, According to a Renalys Pharma media release.
30 Jan 2025 According to a Renalys Pharma media release, company announces completion of patient enrollment in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com